Friday, 6 March 2020

Invisible Orthodontics Market strategies and competitive analysis, forecast till 2023

Market Forecast
Invisible Orthodontics Market reached a value of USD 2598.8 Million in 2018 and is expected to register a CAGR of 13.99% during the assessment period of 2019 to 2025.
Market Synopsis
With the evolving technological advancements in the dental field, the area of invisible orthodontics has gained extensive popularity. Bracket-less aligners, clear retainers, and invisible braces some of the examples of cutting-edge technologies which have been launched in recent years. The high incidence rate of dental diseases in the developing countries and the rising inclination towards the correction of teeth deformities are likely to fuel the growth of the invisible orthodontics market across the globe. For instance, in Brazil, approximately 1.4 million new orthodontic cases are reported every year. Therefore, the key players involved in the invisible orthodontics market are vigorously focusing on product approvals to expand their customer base and brace their position in the market.
Moreover, the field of dentistry is evolving day by day. Public, as well as private organizations, are focusing on catering to the changing needs of the customers in terms of providing demos, conducting campaigns and dental check-ups. Thus, the employment of such strategies will promise the growth of the invisible orthodontics substantially.
Market Influencer
Increasing support by regulatory authorities to the private and public companies, in terms of investment and product approvals, acts as a significant factor that contributes substantially to the growth of the invisible orthodontics market in the longer run.
Market Drivers
  • The increasing prevalence of dental diseases pushes the need for newer treatment options, indirectly fueling the growth of the invisible orthodontics market globally. For instance, 90% of Australians are experiencing tooth decay. Such a high occurrence rate pushes the patients to choose newer techniques and prevention methods, thus fueling the growth of the invisible orthodontics market.
  • Several established players, such as Align Technology, Inc., and Dentsply Sirona are actively involved in getting approvals from regulatory authorities for their products in the invisible orthodontics market. For instance, in March 2017, Align Technology, Inc. launched the Invisalign Teen with mandibular advancement, the first clear aligner solution for Class II correction in growing tween and teen patients. This elucidates the impression that such new approvals are sure to drive the growth of the invisible orthodontics market in the near future.
  • Partnerships and collaborations between key players and local players
  • Increasing technological improvements in the orthodontics industry
  • High investment in research and development for the development of efficient products
  • Growing awareness created by dental professionals and key players about the benefits of clear aligners among the patients
Market Restraints
  • Limitations of invisible orthodontic products. Products such as clear aligners require long treatment time, which is why some of the patients do not prefer these products. In addition, poor compliance of patients with the dentists’ instructions leads to other complications of using these aligners. This results in a decreased target audience which would be utilizing such products, indirectly curbing the growth of the market.
  • Grey market for dental distribution, in terms of illegal selling of products of low quality at a cheaper price
Segmentation
By Product Type
  • Clear Aligners: The clear aligners segment is further segmented into hard, medium, and soft. The hard aligners sub-segment held a market value of an approximate of USD 1,394 million in 2018. The clear aligners segment held the largest share in 2018 due to a number of product launches by key companies such as Align Technology, Inc., Danaher, and others.
  • Braces: This segment has been further divided into ceramic braces and lingual braces. The braces segment is expected to be the fastest-growing during the forecast period owing to the increased awareness about the benefits created by key companies by conducting campaigns and dental check-ups.
  • Clear Retainers: A clear retainer is molded perfectly to fit the new position of the teeth.
By Age Group
  • Below 15: Various companies are getting approvals of their products for adolescents. In March 2017, Align Technology, Inc. launched the Invisalign Teen clear aligner for teenagers. Such increasing initiatives by prominent players for the below 15 age group fuels the growth of this segment.
  • 16-35: People in this age group are highly affected by dental disorders, including bite issues, due to change in lifestyle in recent years. This huge patient pool acts as a perfect target audience for prominent players to develop their products. Thus, the16-35 segment is likely to be the fastest-growing segment during the forecast period.
  • Above 35: The increasing middle-aged and geriatric pool of population suffering from dental caries, weakening of gums, abnormal eruptions in the teeth, among others, are the key factors for the growth of the above 35 segment. The benefits of clear braces are becoming palpable as a growing number of adult patients are now pursuing dental care.
By Application
  • Excessive Spacing: Spacing may prevent the teeth from functioning properly and may also result in gum problems due to the lack of protection provided by the teeth. Therefore, companies are coming up with products for corrective measures and conducting workshops and campaigns to create awareness. Thus, this segment held a majority share in 2018.
  • Crowding: Crowding can either be the result of several other orthodontic problems, such as impacted teeth, and teeth that do not fall out naturally, among others.
  • Malocclusion: The market, based on malocclusion, has been segmented into open bite, deep bite, and crossbite. The malocclusion segment is expected to be the fastest-growing segment during the assessment period owing to the increasing number of patients suffering from crossbites and open bites. Moreover, companies such as Align Technology, Inc. has a portfolio of products which are primarily used for the treatment of malocclusion. Thus, such factors are fueling the growth of this segment.
  • Abnormal Eruptions: Abnormal eruption occurs when a tooth emerges through the gum in the wrong place.
  • Others: Other applications of invisible orthodontic products are for correcting overjets, underbites, and others.
By Region
  • Americas: Americas was the largest regional market in 2018, owing to the continuous activities such as acquisitions, and partnerships employed by prominent players in the major countries in America. For instance, in March 2018, Dentsply Sirona (US) announced the acquisition of OraMetrix (US), a leading industry provider of innovative 3D technology solutions in the field of orthodontics. With this, the company aims to strengthen its position in the American invisible orthodontics market.
  • Europe: The European region holds the second largest share as there is increasing support from regulatory authorities, as well as ample of distributors in the European countries. For instance, in December 2017, Institut Straumann AG (Switzerland) acquired Same Day Solutions (SDS), a dental distribution company in Portugal. This acquisition provided Straumann access to SDS’ customers, which added the sales power and has been helping in supporting the company’s operations in Portugal.
  • Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the global invisible orthodontics market. Direct marketing initiatives by the manufacturers to consumers are playing a substantial role in increasing the target audience and thus increasing the market size in this region. Also, strategic joint ventures by key players are contributing to the growth of the market. For instance, in January 2019, Institut Straumann AG, a company based in Switzerland, entered into a strategic partnership with a Chinese company, Tianjin ZhengLi Technology Company Limited. With this, Institut Straumann AG obtained exclusive distribution rights in China for its clear aligners, and the company aims to leverage its strong marketing and distribution capabilities to penetrate the highly attractive Chinese market. Thus, such strategies are likely to fuel the growth of the Asia-Pacific invisible orthodontics market.
  • Middle East & Africa: The smallest market due to limited healthcare infrastructure. But, in the last few years, top companies operating in the invisible orthodontics market are involved in acquiring different local distributors in the Arabian region to gain foothold in the local markets.
Key Players
  • 3M (US)
  • Align Technology, Inc. (US)
  • Clarus Company (US)
  • ClearPath Healthcare Services (US)
  • Danaher Corporation (US)
  • Dentsply Sirona (US)
  • DynaFlex (US)
  • Henry Schein, Inc. (US)
  • Institut Straumann AG (Switzerland)
  • Ormco (US)

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Biosimulation Market 2023 – Market Size, Share, Trends Analysis and Growth Forecast

According to MRFR analysis, Biosimulation Market is expected to register a CAGR of 15.9% during the forecast period of 2019 to 2025 and is likely to be valued at USD 4.4 Billion by 2025.  
Biosimulation is a tool used for the prediction of the outcomes of existing clinical trials associated with innovation and new drug development.
The growth of the Global Biosimulation Technology Market is determined by numerous factors such as the growing adoption of biosimulation software by regulatory bodies, increasing healthcare expenditure, increasing use of pharmacokinetic & pharmacodynamic modeling in pre-clinical development and rising need to reduce the drug development costs. However, lack of standardization in biosimulation methodology and lack of trained professionals for monitoring biosimulation software are likely to hamper the growth of the global biosimulation market during the forecast period.  
Several market players currently dominate the Global Biosimulation Market. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in September 2019, Certara Inc. launched version 8.2 of Phoenix, the most advanced and widely used validated software for PK, PD, and toxicokinetic modeling and simulation worldwide.
Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
Americas has been segmented into North America and Latin America, with the North American market being divided into the US and Canada. The Americas is projected to hold the largest market share owing to the increasing R&D spending by pharmaceutical and biotechnology companies in the region and growing number of clinical trials & drug development practices.  
The European biosimulation market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The biosimulation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Rising geriatric population and the presence of a large patient pool, are the key factors responsible for the fastest growth of the market in Asia-Pacific. The biosimulation market in the Middle East & Africa has been divided into the Middle East and Africa.
Segmentation
The Global Biosimulation Market has been segmented based on product, application, delivery model and end users.
The market, based on product, has been divided into software and services. The software segment is further segmented into PK/PD (pharmacokinetic/pharmacodynamic) modeling and simulation software, molecular modeling and simulation software, PBPK (physiologically based pharmacokinetic) modeling and simulation software, toxicity prediction software, trial design software, and others. The services segment is further segmented into in-house services and contract services. The software segment is likely to hold the maximum market share in the global biosimulation market owing to growing adoption of biosimulation software by pharmaceutical and research organizations and the increasing R&D investment for pharmaceutical research.
The global biosimulation market based on the application has been segregated into drug development, drug discovery, and others. The drug development segment is expected to hold a larger share of the market share owing to the rising adoption of biosimulation tool for the drug development process.
The delivery model segment of the market is divided into subscription models and ownership models.
Based on end users, the global biosimulation market has been segmented into pharmaceutical and biotechnology companies, contract research organizations, research institutes, regulatory authorities, and others. Rising adoption of inorganic growth strategies by different biosimulation service providers is likely to boost the adoption of biosimulation solutions in the pharmaceuticals and biotechnology companies.
Key Players
Some of the Key Players in the Global Biosimulation Market are Dassault Systèmes (France), Certara USA, Inc. (US), Simulation Plus (US), Schrödinger (US), Chemical Computing Group (Canada), Physiomics (UK), In Silico Biosciences (US), Advanced Chemistry Development, Inc. (Canada), Genedata AG (Switzerland), Nuventra Pharma (US), Evidera (US), Leadinvent Technologies (India), LeadScope, Inc. (US), Rosa (US) and INOSIM Software GmbH (Germany).

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Physical Therapy Equipment Market 2019 – Leading Manufactures, Regions, Drivers, Analysis and Forecasts Till 2025

Market Scenario:
There has been a high level of technological improvement in physical therapy equipment in the past few years, which is fueling the global market growth. Also, as physical therapy equipment is designed specifically to assist people to either regain or improve their physical abilities; thus, number of companies are investing in this market.
The Global Physical Therapy Equipment Market is expected to hold a value of USD 19,100 Million by 2025 at a CAGR of 6.21%, says Market Research Future in Physical Therapy Equipment Market Forecast 2020.
Market Influencer
The increasing initiatives by public and private companies boost market growth. The growing number of equipment launches also acquisitions and mergers of key players in the market are likely to act as a promising factor for the growth in the near future.  For instance, in February 2019, Colfax acquired DJO Global, Inc. for USD 3.15 billion. This helps Colfax to widen its product portfolio in the orthopedic segment.
Market Drivers
  • Growing prevalence of orthopedic disorders
  • Rising geriatric population
  • Rising incidence of sport injuries
  • Increasing awareness about physical therapy equipment
  • Rising incidences of road accidents
  • Huge number of R&D activities in the field of physiotherapy
  • Upsurging support by public and private companies
  • Increasing mergers and acquisitions by prominent players in the market. For instance, in April 2017, Dynatronics’s acquired Hausmann Industries, a manufacturer of branded, high-quality physical therapy and athletic training products. With this acquisition, the company aimed to increase business in the physical therapy equipment market
  • Growing government schemes promoting the use of rehabilitation equipment
Market Restraints
  • Inadequate reimbursement policies for physiotherapy
  • Lack of trained and skilled personnel
Segmentation
By Product
  • Equipment: Expected to hold the largest share, owing to the wide range of applications it offers. The type of equipment is electrotherapy equipment, ultrasound equipment, exercise therapy equipment, cryotherapy equipment, combination therapy equipment, continuous passive motion (CPM) therapy equipment, shockwave therapy equipment, laser therapy equipment, traction therapy equipment, magnetic therapy equipment, and others.
  • The use of physical therapy equipment is increased due to the global increase in orthopedic diseases. For example, approximately 80% of Americans will experience back problems at some point in their lives.  Also, an estimated 10% of the world’s population suffers from lower back pain.
  • Accessories: This is expected to be the fastest segment attributed to increasing use of physical therapy equipment for the cure of musculoskeletal diseases. The accessories segment is further divided into two types, namely, physiotherapy furniture and physiotherapy tapes and bandages.
By Application
  • Musculoskeletal Applications: Expected to hold the largest share, owing to increasing incidence of musculoskeletal disorders and also increasing the geriatric population.
  • Neurological Applications: This is expected to hold the fastest segment is attributed to an increase in prevalence of neurological diseases such as paralytic attacks and strokes.
  • Cardiovascular & Pulmonary Applications: The cardiovascular and pulmonary applications segment is witnessing significant growth due to increasing prevalence of cardiovascular diseases and chronic obstructive pulmonary disease (COPD).
  • Pediatric Applications: Increased use of physical therapy for musculoskeletal (MSK) disorders in children.
  • Gynecological Applications: The role of physiotherapy is in obstetrics and gynecology involves pregnancy, labor, and the puerperium, preoperative, and postoperative periods.
  • Others: Other applications include rehabilitation centers where the use of physical therapy is increasing.
By End-User
  • Hospitals and Clinics: Hospitals and clinics are expected to hold the largest segment due to usually a large patient pool and advanced physical therapy setups in hospitals based on the need of patients. Growing awareness about new physical therapy is projected to drive the growth of this segment during the forecast period.
  • Physiotherapy Centers: Expected to hold the fastest segment, owing to growing awareness about new physical therapy among the population.
  • Home Care Settings: Many companies launching the range of physical therapy devices available for use at home.
By Region
  • Americas: The largest regional market. Countries such as the US and Canada have well-established physical therapy centers which constitute advanced physical therapy systems and instruments. This contributes to the growth of the physical therapy equipment market in this region.
  • Europe: The Europe market is expected to hold the second-largest market due to increasing prevalence of neurological disorders, orthopedic problems coupled with cardiopulmonary diseases in the region.
  • Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the global physical therapy equipment market. This is due to the increasing geriatric population and a large number of patients suffering from neurological diseases in China and Japan.
  • Middle East & Africa: The smallest market due to limited healthcare infrastructure and limited exposure to technological advancements.
Key Players
  • DJO Global, Inc. (US)
  • BTL Industries (US)
  • Enraf-NoniUS B.V (Europe)
  • Dynatronics Corporation (US)
  • EMS Physio (UK)
  • ITO Co. Ltd (Japan)
  • Mectronic Medicale (Europe)
  • Performance Health (Subsidiary of Madison Dearborn Partners) (US)
  • Whitehall Manufacturing (US)
  • Zimmer Medizinsysteme GmbH (Germany)
  • Colfax Corporation (US)
  • STORZ MEDICAL (US)
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Medical Writing Market Size, Share Analysis, Strategies, Revenue and Forecasts to 2025

Increasing demand for regulatory paperwork in the pharmaceutical and biopharmaceutical industry is expected to drive the growth of the medical writing market. Pharmaceutical medical writing has grown significantly in India in last few years. Medical writing includes preparing regulatory paperwork and publication of documents related to health, diseases, and healthcare products. It requires medical knowledge and understanding of drug development and regulatory guidelines. Medical writing plays a vital role in the success of a clinical research project. An increase in healthcare spending is expected to drive the growth of the global medical writing market.
Strategic mergers & acquisitions are also projected to boost market growth with companies looking to strengthen their market positions and expand their product portfolios. For instance, in May 2019, ICON acquired MediNova, an integrated network of clinical research sites across Europe, Middle East & Africa. The acquisition helped ICON strengthen its position exponentially in the medical writing market.
The Global Medical Writing Market Size is expected to cross USD 3.25 Billion by 2025 at a CAGR of 10.1 %.
An increase in research and development (R&D) investment and the expiration of patents are directly linked to the growth of the market.
Segmentation
The global medical writing market has been segmented based on type, application, and end user.
The market, based on type, has been divided into clinical writing, regulatory writing, scientific writing, disease- and drug-related writing, and others. The clinical writing segment is likely to be the largest during the review period due to increasing investment made by pharmaceutical industries, and other government bodies are investing in clinical trials globally. The regulatory writing segment is predicted to be the fastest-growing. Regulatory writing includes different clinical documents which include treatment of various disorders and contains descriptions of clinical trials.
The global medical writing market has been segregated, based on application, into medical journalism, medical education, and medico marketing. The medical journalism segment is expected to hold the majority share of the market. It is one of the most significant segments due to the growing need for multiple reliable sources of medical information and update on current treatment methodologies in the drug industry. The medical education segment is expected to be the fastest-growing due to the increasing use of various medical notebooks and online research articles to analyze multiple chronic disorders.
The end user segments of the market are pharmaceutical & biotechnology companies and contract research organizations (CROS). The pharmaceutical & biotechnology companies segment is expected to hold the largest share of the market as the use of medical writing is highest in pharmaceutical companies.
Regional Analysis 
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the increasing prevalence of medical writing and rising per capita healthcare expenditure. The medical writing market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European medical writing market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The medical writing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing patient pool of medical writing and rising awareness about the treatment methods, the market in Asia-Pacific is expected to be the fastest-growing. The medical writing market in the Middle East & Africa has been divided into the Middle East and Africa.
Key players for Global Medical Writing market
Some of the key players in the Global medical writing market are  Cactus Communications (UK), Covance Inc (US), SIRO CLINPHARM (India), IQVIA (US), OMICS International (India), Freyr Solutions (US), SYNCHROGENIX (US), INCLIN, INC (US), and Clinexa Life Sciences Pvt (Australia), and Parexel International Corporation (US).
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Global Diabetic Neuropathy Treatment Market Set for Big Growth - Foresight by 2025

Market Scenario:
The Global Diabetic Neuropathy Treatment Market is expected to cross USD 5.80 Billion by 2025 at a CAGR of 5.1%.
Market Synopsis
The number of diabetic neuropathy cases is increasing globally, fueling market growth. Diabetic neuropathy treatment is the second-highest contributor to global disability and an estimated 30% to 40% of people across the globe live with diabetic neuropathy.
Diabetic neuropathy is most common in low- and middle-income countries, and this disorder requires lifelong care to manage.
Market Influencer
The rising prevalence of diabetic disorders and increasing reimbursement offered to patients by health insurance providers.
Market Drivers
  • Growing global geriatric population.
  • Change in lifestyle habits leading to bad posture, which is increasing the prevalence of diabetic neuropathy disorder.
  • Increasing research and development of new drugs to treat diabetic neuropathy disorder.
  • Rising prevalence of diabetic neuropathy. For example, the prevalence of diabetic neuropathy in the fiscal year 2000 to 2030 will reach up to 366 million people in the US.
  • Rising awareness of advanced treatments for diabetic neuropathy.
  • Launch of a new medication to manage the symptoms of chronic diabetic neuropathy.
Market Restraints
  • High treatment costs.
  • Availability of alternative therapies such as traditional medicine and physiotherapy.
  • Need for specialized equipment to diagnose and treat diabetic neuropathy.
Segmentation
By Disorder
  • Peripheral Neuropathy: The largest segment of the market, peripheral neuropathy afflicts almost 1% of the entire global population and is three times as likely to afflict women than men.
  • Autonomic Neuropathy: This disorder generally afflicts elderly people. As of 2018, about 23 million people in the US had autonomic neuropathy and over a quarter of those afflicted could not perform daily activities.
  • Proximal Neuropathy: It is a rare type of nerve damage that occurs in hip, buttock, or thigh. It typically affects one side of the body and rarely spreads to the other side of the body. About 50% of patients suffering from diabetes have proximal neuropathy.
  • Focal Neuropathy: This focal neuropathy disorder afflicts roughly 3 out of every ten individuals who have diabetes with over 100 million people affected globally.
By Treatment
  • Drugs: The fastest-growing segment of the market, drugs are most widely used for the treatment of diabetic neuropathy. A rise in the number of FDA approvals for drugs to treat diabetic neuropathy is a key factor for the growth of the segment.
  • Transcutaneous Electrical Nerve Stimulation (TENS): The largest segment, TENS is the preferred treatment for many diabetic neuropathies as they reduce inflammation and suppress immune system activity.
  • Others: The other segment includes physiotherapy and electroacupuncture and various other treatment options for diabetic neuropathy.
By End-User
  • Hospitals and Clinics: The largest segment, hospitals, and clinics are usually the primary points for diagnosis, treatment, and rehabilitation of individuals afflicted with diabetic neuropathy. Growing awareness and increasing efficiency of diabetic neuropathy treatment are projected to drive the growth of this segment during the forecast period.
  • Retail Pharmacy: A small segment. This center provides immediate pain relief and rudimentary drugs for diabetic neuropathy.
  • Online Pharmacy: Various drugs are used for the treatment of diabetic neuropathy which can be easily available in online pharmacy.
  • Others: This segment includes home care and senior citizen centers.
By Region
  • Americas: The largest regional market. The prevalence of diabetic neuropathy is high in the Americas. The region also has a well-established healthcare industry. Out of the entire population, around 72.2% people in the US were suffering from diabetic neuropathy in 2017.
  • Europe: An increasing geriatric population is leading to a rise in the number of diabetic neuropathy disorder cases.
  • Asia-Pacific: The fastest-growing regional market. Asia-Pacific is seeing a surge in the number of people afflicted with diabetic neuropathy due to bad posture brought on by lifestyle changes, aging, and genetic predisposition. Diabetic neuropathy is an increasing problem in Asia. Approximately 4000 patients were diagnosed with diabetic neuropathy in Korea in 2017, whereas in Japan, around 298 people were diagnosed with diabetic neuropathy in 2017.
  • Middle East & Africa: The smallest market due to limited healthcare infrastructure and a very young population.
Key Players
  • Abbott Laboratories (US)
  • Hoffmann-La Roche Ltd (Switzerland)
  • Eli Lilly and Company (US)
  • Johnson & Johnson (US)
  • GlaxoSmithKline Plc (UK)
  • Lupin Limited (India)
  • Glenmark Pharmaceuticals Limited (India)
  • Depomed, Inc. (US)
  • Astellas Pharma Inc (Japan)
  • Pfizer Inc (US)
  • MEDA Pharma GmBH & Co. KG (Germany)
  • Others
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Lactose Intolerance Treatment Market Professional Overview 2019-2023 with Major Vendors Size, Shares and Worldwide Demand

Market scenario:
The Global Lactose Intolerance Treatment Market is expected to register a CAGR of 7.10% and reach USD 41,054.4 Million by 2025. Lactose Intolerance treatment is a digestive problem with an impaired ability to digest lactose. Factors such as rising cases of gastrointestinal disorders, increasing awareness about Lactose Intolerance treatment and related complications, and increased prevalence of Lactose Intolerance treatment are the driving forces for the market. However, side-effects associated with supplements is projected to restraint the market during the forecast period (2019-2025).
Market Dynamics
Lactose Intolerance treatment is a medical condition identified by lactase (lactose digesting enzyme) deficiency within the patient’s body. As a result, lactose remains intact and unabsorbed producing various ill-effects such as flatulence, bloating, abdominal pains, and others. There are four types of lactose intolerance, namely, primary lactase deficiency, secondary lactase deficiency, congenital lactase deficiency, and developmental lactase deficiency. Secondary lactase deficiency mainly occurs due to irritable bowel syndrome (IBS), gastroenteritis, Crohn disease, ulcerative colitis, celiac disease, chemotherapy, and antibiotics. As per the study suggested by the Journal of Health, Population, and Nutrition in 2017, the prevalence of Lactose Intolerance treatment was significantly higher in IBS-D patients than in healthy individuals. In this study, some eligible IBS-D patients and healthy individuals were enrolled. In the enrolled individuals, lactose malabsorption was diagnosed by a lactose hydrogen breath test (HBT), and lactose intolerance-related symptoms were monitored for eight hours following lactose administration. It was found that the prevalence of lactose malabsorption was 72% in IBS patients and 60% in healthy individuals.
Segmentation
The global Lactose Intolerance treatment market has been segmented by type of lactose intolerance, treatment, form, and end user. The market, based on type, has been bifurcated into primary lactose intolerance, secondary lactose intolerance, and congenital/developmental lactose intolerance. Based on form, the Lactose Intolerance treatment market has been segregated into food supplements, enzyme lactase supplements, probiotics, and others (combination products and prebiotics). By form, the global Lactose Intolerance treatment market has been segmented into tablets/capsule, powder, and liquid. On the basis of end-user, the market has been divided into home care and hospitals & clinics. 
The food supplements segment, by treatment is estimated to hold a share of 70.4% in the market.
Regional Analysis
The global Lactose Intolerance treatment market, on the basis of region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
Europe held the major market share of 42.0% in 2018. The dairy consumption in Western Europe is good in comparison to other regions of Europe and has a high per-capita consumption rate throughout the region. The Americas held the second largest market share of 28% in 2018. It is further segmented into North and Latin America. The consumption of dairy products is also distinct and variable in the Americas. Latin America, for example, is one of the fastest-growing dairy markets in the world. Consumers in this region are looking for more convenient ways to shop. They seek to purchase products from a single location or store, and it is one of the main drivers of hypermarkets and supermarkets in Latin America. Asia-Pacific is the third-largest region and held the market share of 20.0% in 2018. In terms of value, it has the largest dairy consumption, but it has the lowest per capita income spent on dairy products as it is still developing better infrastructure for the distribution of chilled dairy products. The Middle East and Africa is highly obsolescence with per capita spend on dairy at just USD 25 per head, the lowest in the world.
Key Players
The prominent players in the global are Abbott Laboratories, Inc. (US), Nestle (Switzerland), Cargill, Incorporated (US), Dean Foods (US), Johnson & Johnson, Inc. (US), and Novozyme, (Denmark) are some of the major players in the market.
Some of the key strategies followed by players operating in the global Lactose Intolerance treatmentmarket were innovation, product development, and acquisition & mergers.
  • In March-2018, Nestlé completed its acquisition of Atrium Innovations Inc., a global leader in nutritional health products. This acquisition supports Nestlé’s pursuit of growth opportunities in consumer healthcare to complement the company’s focus on its high-growth food and beverage categories
  • In April-2017, Abbott introduced science-based nutrition drinks to help patients have a better recovery from surgery. New Ensure Surgery Immunonutrition Shake and Ensure Pre-Surgery Clear Nutrition Drink is designed for hospitals implementing surgical guidelines for enhancing patient recovery. These drinks are also lactose-free.
  • In May,2016- Dean Foods launched a new DairyPure brand, lactose free milk to its line of dairy products. DairyPure lactose-free milk delivers real dairy nutrition and delicious taste. Also, it is 100% lactose-free, making it easy to digest for those with lactose sensitivities.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Thursday, 5 March 2020

Meningococcal Vaccines Market Growth and Restrain Factors Analysis By 2023

Global Meningococcal Vaccines Market Overview by Treatment (Meningococcal Conjugate Vaccine, Polysaccharide & Subcapsular Vaccine) and End User (Hospitals & Clinics, Research Laboratories and Academic Institutes) - Forecast till 2025
Market Forecast
Meningococcal Vaccines Market has a demand for USD 172 Million doses in 2019. Further, the global estimated supply in 2019 is expected to be 203 Million doses.
Market Synopsis
Meningococcal meningitis is a bacterial infection caused by Neisseria meningitides. Disease incidence is high in West and Central Africa, where historically, serogroup A has been the most important cause of disease. More recently, meningitis outbreaks have gradually been associated with serogroup C, and to a lesser extent, serogroup W.
The meningococcal vaccines market is complex and diverse, with regional variations in serogroup distribution with substantial use outside routine immunization. The vaccine has approximately 29 marketed products targeting various combinations of the six serogroups (A, B, C, W, X, Y).
Market Influencer
Without an increase in production, the existing supply of conjugate MenACWY will be inadequate to meet the demand generated by the rising incidence of serogroups C and W, and the low availability of polysaccharide vaccines. Further, several multivalent, conjugate vaccines by Chinese and Indian manufacturers are in the pipeline, and, if prequalified they will be registered for use in many geographies. Moreover, if they are made available at acceptable prices it could increase global demand in Meningococcal Vaccines Market Trends.
Market Drivers
  • Rise in prevalence of the meningococcal disease
    • According to a document published by the U.S. Department of Health & Human Services, in 2017, there were approximately 350 cases of meningococcal disease reported. The disease has an incidence rate of 0.11 cases per 100,000 people in the United States. Any population group can be affected by the disease, with maximum prevalence in children younger than one-year-old and a second peak in adolescence. Adolescents and young adults, ranging from 16 to 23 years old, have the highest rates of meningococcal disease.
    • Further, increasing incidence of meningococcal disease in West and Central Africa regions is expected to drive the demand in the African region
  • Booming mortality of the meningococcal disease is leading to increasing demand for the vaccines
    • Approximately 10 to 15 in 100 people affected with meningococcal disease will face mortality. Further, up to 1 in 5 survivors will have long-term disabilities, such as loss of limb, deafness, and damage to the nervous system brain among others
  • Escalating positive results with the vaccines to boost the demand in the market
  • Growing research and development activities by prominent players in the industry
Market Restraints
  • Withdrawn production of polysaccharide vaccines has resulted in reduced country access, particularly for MICs in various regions. For example, Sanofi Pasteur, manufacturer of Menomune, declared in 2017 that the company is discontinuing the production of the vaccine. With the production of Menomune at hold, there were no polysaccharide vaccines approved for use in the United States

Meningococcal Vaccines Market Segmentation

By treatment, the market is segmented into Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine.
Meningococcal A conjugate vaccine is significantly used in mass campaigns across affected regions like Africa. Since 2010, the vaccine has significantly decreased meningococcal disease incidence in the region. However, the demand for meningococcal A conjugate in the country remains uncertain given that national immunization program adoptions are based on the timing of Gavi funding decisions, the country’s readiness, and competing for vaccine introduction priorities.
In the polysaccharide segment, products such as MenACWY vaccines are in high demand. MenACWY vaccine is the most desirable combination, given its broader serotype coverage. MenACWY specifically has nine products that are available across polysaccharide and conjugate product segments, but conjugate products are suggested for use in routine immunization activities.
Moreover, the demand and supply of Subcap MenB vaccines is restricted to HICs and influenced by their acceptance into NIPs. Improved uptake of MenB vaccines is expected in the coming years but will likely be moderate and limited to high-income markets given the high price and competing interest of introducing MenACWY conjugate.
By end-user, the market is segmented into Hospital & Clinical, Research Laboratories, and Academic Institutes
Hospitals and clinics control the global market for meningococcal vaccines. The high growth of hospitals and clinics segment is attributed to the increasing application of vaccines in these healthcare facilities in conjunction with the growing prevalence and incidence of the meningococcal disease.
Moreover, research laboratories and academic institutes take up the second-largest share due to the boost in research and development in the market.
By region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
In the global market, China is expected to have the largest market share, which accounts for approximately 35% of the global demand. This is primarily due to polysaccharide products, which currently comprise 84% of China’s demand. Chinese suppliers presently focus only on meeting the demand of the domestic market, but some of the manufacturers have indicated interest in the global market as well. The dynamic product pipeline with several multivalent conjugate products in development may trigger changes in the future supply mix of the Chinese market. Moreover, in China, non-routine use (excluding campaigns) accounts for an estimated 9 million doses in 2019, which may help to sustain the huge market share in the forecast period.
UNICEF foresees all 26 African countries in the meningitis belt, which have completed mass campaigns in 2016. In 2015, seven countries in the region were introduced with meningococcal A conjugate vaccine through their mass campaigns and targeted a population of 233 million. Further, during 2016-2018, UNICEF introduced meningococcal A conjugate vaccine in 26 countries. Ghana was the first country to be introduced with the vaccine into its RI schedule in 2016. Also, four other countries including Mali, Niger, Nigeria, and Sudan introduced the vaccine into RI programs in 2016.
Key Developments in the Global Meningococcal Vaccines Market
  • In 2018, Pfizer granted FDA Breakthrough Therapy designation for Trumenba (Meningococcal Group B Vaccine). This vaccine plays a major role in the prevention of invasive meningococcal B disease in children aged 1 to 9 years
  • In 2018, GSK’s meningitis B vaccine Bexsero received Breakthrough Therapy designation from the US FDA for prevention of Invasive Meningococcal Disease for children 2-10 years of age
  • In 2015, Novartis Bexsero vaccine was approved by the FDA for the prevention of meningitis B. This vaccine is used as active immunization to prevent invasive meningococcal disease caused by serogroup B
Key Players
  • Baxter international
  • Pfizer Inc.
  • Sanofi S.A.
  • Novartis Pharmaceuticals Inc.
  • JN-International Medical Corporation
  • Serum Institute of India Ltd.
  • GlaxoSmithKline
  • BIO-MED
  • Others
Browse more Healthcare Reports @
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)